Durvalumab 120 mg/4 mL, 500 mg/10 mL Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 120 mg/4 mL, 500 mg/10 mL
Reference Brands: Imfinzi® (US & EU)
Category: Oncology Cancer Care
Durvalumab (Imfinzi®) is a PD-L1 checkpoint inhibitor used for urothelial carcinoma and NSCLC treatment. Available as sterile intravenous infusion vials (120 mg/4 mL, 500 mg/10 mL), it complies with EU-GMP and USFDA standards. Offered for B2B supply, hospital tenders, and licensing in regulated markets.
Manufacture or export Durvalumab? List it or send an offer →
Product Description:
Durvalumab (Imfinzi®) is a PD-L1 immune checkpoint inhibitor indicated for urothelial carcinoma and non-small cell lung cancer. Provided as sterile intravenous infusion vials (120 mg/4 mL and 500 mg/10 mL), Durvalumab is manufactured under EU-GMP and USFDA standards. Available for B2B supply, contract manufacturing, and licensing, it supports hospital tenders and oncology distributors with full regulatory documentation. This monoclonal antibody enhances anti-tumor immunity by blocking PD-L1, making it a critical drug in immuno-oncology portfolios across the US and European markets.
Also known as: durvalumab (Spanish, French, Italian, Indonesian), durvalumabe (Portuguese), Durvalumab (German), дурвалумаб (Russian), دورفالوماب (Arabic), 度伐利尤单抗 (Chinese), デュルバルマブ (Japanese).
Durvalumab — third party manufacturing & bulk supply
Durvalumab 120 mg/4 mL, 500 mg/10 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Durvalumab is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Durvalumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Durvalumab →Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.
Frequently Asked Questions
Durvalumab is used to treat certain types of cancer, including unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy and extensive-stage small cell lung cancer (ES-SCLC) in combination with chemotherapy. It is also indicated for advanced or metastatic urothelial carcinoma. Durvalumab works by helping the immune system detect and attack cancer cells more effectively.
Durvalumab is a fully human monoclonal antibody made using recombinant DNA technology. It specifically targets and blocks the programmed death-ligand 1 (PD-L1) protein on cancer cells, which allows T cells to recognize and destroy these cells. The active ingredient is Durvalumab, and inactive components include histidine, sucrose, polysorbate 80, and water for injection.
The trade name of Durvalumab is Imfinzi.
Durvalumab is developed and manufactured by AstraZeneca Pharmaceuticals LP, a leading global biopharmaceutical company headquartered in the United Kingdom.
The generic name of the product is Durvalumab.
The brand name of the product is Imfinzi.
Durvalumab (Imfinzi) is manufactured by AstraZeneca at facilities located in the United Kingdom and the United States, and it is also produced in other AstraZeneca manufacturing sites in Europe to meet global demand.
El durvalumab es un anticuerpo monoclonal anti-PD-L1, un tipo de inmunoterapia, aprobado para algunos tipos de cáncer de pulmón (de células no pequeñas y de células pequeñas) y, según el país, para otros tumores como el cáncer de vías biliares y el carcinoma hepatocelular. Se administra por infusión intravenosa en el hospital, bajo la supervisión de oncólogos. PharmaTradz apoya a importadores, distribuidores y hospitales con licencia en el abastecimiento de durvalumab de fabricantes con certificación GMP.
O durvalumabe é um anticorpo monoclonal anti-PD-L1, um tipo de imunoterapia, aprovado para alguns tipos de câncer de pulmão (de não pequenas células e de pequenas células) e, conforme o país, para outros tumores, como o câncer das vias biliares e o carcinoma hepatocelular. É administrado por infusão intravenosa em ambiente hospitalar, sob supervisão de oncologistas. A PharmaTradz apoia importadores, distribuidores e hospitais licenciados no fornecimento de durvalumabe de fabricantes com certificação GMP.
Le durvalumab est un anticorps monoclonal anti-PD-L1, une forme d’immunothérapie, autorisé dans certains cancers du poumon (non à petites cellules et à petites cellules) et, selon les pays, dans d’autres tumeurs comme le cancer des voies biliaires et le carcinome hépatocellulaire. Il est administré en perfusion intraveineuse à l’hôpital, sous la surveillance d’oncologues. PharmaTradz soutient les importateurs, distributeurs et hôpitaux agréés dans leur approvisionnement en durvalumab auprès de fabricants certifiés BPF (GMP).
Related Products
Sunitinib
Strength:
12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View Details
Atezolizumab
Strength:
1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details
Ifosfamide
Strength:
1 g/vial,2 g/vial, 3 g/vial
Form: Injection
Reference Brands: Ifex® (US), Holoxan® (EU)
View Details
Docetaxel 160 mg Injection
Strength:
20 mg/0.5 mL, 80 mg/2 mL, 160 mg/4 mL
Form: Injection
Reference Brands: Taxotere (US & EU)
View Details
Quizartinib Dihydrochloride
Strength:
17.7 mg , 26.5 mg
Form: Tablets
Reference Brands: Vanflyta (USA/EU)
View Details
Abemaciclib
Strength:
50 mg, 100 mg, 150 mg, 200 mg
Form: Tablets
Reference Brands: Verzenio (USA)
View Details
Panitumumab
Strength:
100 mg/5 mL
Form: Solution for Infusion
Reference Brands: Vectibix (USA/LATAM)
View Details
Ramucirumab
Strength:
100 mg/10 mL
Form: Solutions for disinfection
Reference Brands: Cyramza (USA)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit
